Current development in nanoformulations of docetaxel

Area of Science:

• Drug delivery systems
• Nanotechnology in medicine
• Cancer therapeutics

Background:

• Docetaxel (DTX) is a potent anti-cancer drug, but its clinical use is limited by side effects from its solvent (Tween 80 and ethanol).
• Nanoformulations offer a promising approach to improve DTX delivery by facilitating transport into tumor cells and enabling targeted binding.
• Various nano-sized carriers are being explored for enhanced DTX delivery.

Purpose of the Study:

• To review nanoformulations for Docetaxel (DTX) delivery.
• To cover preparation, physicochemical properties, and in vitro/in vivo actions of DTX nanoformulations.
• To discuss challenges in developing DTX nanoformulations.

Main Methods:

• Focus on nanoformulations for DTX delivery.
• Review of preparation and physicochemical properties.
• Analysis of in vitro and in vivo actions against tumor cells.

Main Results:

• Nanoformulations like liposomes, micelles, nanoparticles, and nanoemulsions improve DTX solubility, activity, and in vivo distribution.
• These systems aid DTX transport through tumor vasculature and cellular uptake.
• Targeted modifications enhance binding to cancer cell-specific sites.

Conclusions:

• Despite improvements, significant hurdles remain for DTX nanoformulations.
• Challenges include quality control, stability, large-scale production, and manufacturing technology.
• Further research is crucial for clinical and commercial viability of DTX nanoformulations.